FDA Greenlights First Once-Weekly Basal Insulin: A New Era for Type 2 Diabetes Care

The landscape of diabetes management has shifted. On March 27, 2026, the FDA officially approved Awiqli® (insulin icodec-abae), marking the arrival of the first and only once-weekly basal insulin for adults living with type 2 diabetes.

This breakthrough replaces the traditional 365-day injection cycle with just 52 doses per year, offering a significant reduction in treatment burden for millions of patients.

The Science Behind the Weekly Dose

The approval is anchored by the ONWARDS phase 3a clinical program, a massive undertaking involving approximately 2,680 adults. Key findings from the trials include:

Proven Efficacy: Awiqli® met its primary goal of reducing HbA1c levels, demonstrating effectiveness comparable to daily basal insulins.
Versatile Use: The studies evaluated the weekly injection alongside mealtime insulin, oral medications, and GLP-1 receptor agonists.
Consistent Safety: Researchers found the safety profile of Awiqli® to be overall consistent with the well-established daily basal insulin class.

Redefining the Routine

Delivered via the FlexTouch® device, Awiqli® (700 units/mL) is designed to fit seamlessly into diverse lifestyles. By moving from a daily requirement to a “same day each week” schedule, the medication aims to improve adherence and quality of life for those struggling with the frequency of daily injections.

Looking Ahead

Novo Nordisk plans to launch Awiqli® in the United States in the second half of 2026. While the drug is already approved in the EU and 13 other countries, this FDA clearance provides a critical new alternative for the U.S. healthcare market at a time when innovation in insulin therapy is more vital than ever.

Important Note: Awiqli® is a prescription-only medication indicated specifically for adults with type 2 diabetes as an adjunct to diet and exercise.